All News

All News2019-08-30T13:20:18-03:00

BioVectra Inc. hosts roundtable discussion with Minister Bernadette Jordan and other key Windsor community stakeholders to discuss planned five-year, $144.6 million expansion project

BioVectra Inc. hosts roundtable discussion with Minister Bernadette Jordan and other key Winsor community stakeholders to discuss planned five-year, $144.6 million expansion project

Windsor, Nova Scotia, Canada (March 7, 2019) – On March 6, 2019, BioVectra Inc., an Atlantic Canadian Contract Development and Manufacturing Organization (CDMO), hosted a roundtable discussion at its Windsor, Nova Scotia facility to discuss the local impact of the planned five-year, $144.6 million expansion project announced on March 4 in Charlottetown, PEI. Community roundtable voices included Bernadette Jordan, Minister of Rural Economic Development, the Atlantic Canadian Opportunity Agency (ACOA), Innovation, Science and Economic Development (ISED), municipal leaders including Mayors Anna Allen and Peter Muttart, key industry association leaders, Acadia University and Nova Scotia Community College (NSCC) representatives, and local business representatives.

In support of the expected $144.6 million expansion project, BioVectra received a $37.5 million investment through the Government of Canada’s Strategic Innovation Fund. Over the five-year lifespan of the project, the company intends to create 150 jobs in Atlantic Canada, with 110 anticipated in Windsor, Nova Scotia.

“We’re proud to be a partner with BioVectra in creating well-paying jobs here in the Maritimes. This funding will allow BioVectra to expand its manufacturing capacity and start research and development of advanced pharmaceutical products not currently manufactured in Canada, helping to position the Maritimes as an innovative hub for these products that save lives.” – The Honourable Bernadette Jordan, Minister of Rural Economic Development

The roundtable discussion focused on understanding and supporting the project itself, but also on leveraging the collective contributions and strengths of all stakeholders in creating a climate to capture and create more opportunities like this one for long-term regional growth. “This invaluable exchange was focused on community collaboration,” said BioVectra’s Windsor General Manager, Heather Delage. “This discussion was all about building momentum and bringing the right people to the table that can help create an environment and action plan to support our investment.”

About BioVectra

BioVectra is a CDMO that serves global pharmaceutical and biotech companies with full-service cGMP outsourcing solutions for intermediates and active pharmaceutical ingredients. An innovative and reliable service partner with a strong regulatory history, BioVectra has over 45 years of experience specializing in:

  • cGMP Microbial Fermentation
  • Complex Chemistry – High Potency APIs
  • Biologics
  • Formulation Development

For more information about BioVectra, please visit www.biovectra.com.

Media Contact

Jordan MacGregor
Communications and Marketing Manager
BioVectra Inc.
Phone: 902-566-9116 ext. 6376
E-Mail: jmacgregor@biovectra.com


Statements in this document that are not strictly historical, including statements regarding future business prospects, use of capital or the impact of any such events or developments, and any other statements regarding events or developments the company believes or anticipates will or may occur in the future, may be “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, and involve a number of risks and uncertainties. There are a number of important factors that could cause actual events to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. The forward-looking statements made herein speak only as of the date hereof and the company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise, except as required by law.

March 7th, 2019|News|

BioVectra Inc. announces a $144.6 million expansion project, including a $37.5 million contribution through the Government of Canada’s Strategic Innovation Fund

BioVectra Inc. announces a $144.6 million expansion project, including a $37.5 million contribution through the Government of Canada’s Strategic Innovation Fund

— Prime Minister Justin Trudeau visits BioVectra to announce Government of Canada investment in Atlantic Canadian CDMO and high-skilled jobs creation in the region —

Charlottetown, Prince Edward Island, Canada (March 4, 2019) – Today, BioVectra Inc., an Atlantic Canadian Contract Development and Manufacturing Organization (CDMO), announced a five-year, $144.6 million (CAD) expansion project to enhance its Biopharmaceutical capabilities in both Charlottetown, Prince Edward Island and Windsor, Nova Scotia.

Prime Minister, Justin Trudeau, visited BioVectra in Charlottetown to announce a $37.5 million contribution from the Government of Canada through the Strategic Innovation Fund (SIF). The $37.5 million contribution represents the single largest SIF Project ever awarded in Atlantic Canada.

“Thanks to innovations in life sciences, Canadians are living longer, healthier lives than ever before. Canadian companies like BioVectra are creating new jobs and establishing themselves as global leaders in producing lifesaving treatments for serious illnesses that affect millions of people around the world. Today, we are not only investing in an innovative Canadian business, but also in Canadians and the future prosperity of our country.” – The Rt. Hon. Justin Trudeau, Prime Minister of Canada

More specifically, the project is intended to support BioVectra’s on-going Active Pharmaceutical Ingredients (APIs) production capacity expansion in Charlottetown, as well as an expansion of its Biologics capabilities in Windsor, including a mammalian cell culture facility.

Over the project’s five-year lifespan, 150 high-skilled, full-time jobs are expected to be created on Prince Edward Island and in Nova Scotia. “We are pleased to announce plans to create 150 additional jobs, 110 to be located at our Windsor site and 40 in Charlottetown,” said BioVectra President, Oliver Technow. “This is an extremely proud day for BioVectra, and we are deeply appreciative of the government’s support. Since 2015, we have invested approximately $25 million per year in expansions and technologies that have vastly enhanced our capabilities. Today’s announcement is a continuation of our commitment to growth right here in Atlantic Canada!”

As a trusted and innovative partner, BioVectra’s global client base includes most of the top 20 biopharmaceutical companies in the world. “Our clients develop important, life-saving medicines for people all around the globe,” said BioVectra’s Windsor General Manager, Heather Delage. “This exciting expansion project is designed to help propel us toward being a top-tier player in the biologics field, where many therapies are advancing rapidly, and changing the way healthcare is delivered.”

Beyond these expansion plans, BioVectra intends to complement its existing academic partnerships by forming additional collaborations with Canadian academic institutions. This investment includes reinforcing its future talent base by providing over 25 students with on-the-job training and internship opportunities on an annual basis.

About BioVectra

BioVectra is a CDMO that serves global pharmaceutical and biotech companies with full-service cGMP outsourcing solutions for intermediates and active pharmaceutical ingredients. An innovative and reliable service partner with a strong regulatory history, BioVectra has over 45 years of experience specializing in:

  • cGMP Microbial Fermentation
  • Complex Chemistry – High Potency APIs
  • Biologics
  • Formulation Development

For more information about BioVectra, please visit www.biovectra.com.

Media Contact

Jordan MacGregor
Communications and Marketing Manager
BioVectra Inc.
Phone: 902-566-9116 ext. 6376
E-Mail: jmacgregor@biovectra.com


Statements in this document that are not strictly historical, including statements regarding future business prospects, use of capital or the impact of any such events or developments, and any other statements regarding events or developments the company believes or anticipates will or may occur in the future, may be “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, and involve a number of risks and uncertainties. There are a number of important factors that could cause actual events to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. The forward-looking statements made herein speak only as of the date hereof and the company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise, except as required by law.

March 4th, 2019|News|

BioVectra Inc. excited for continued growth under experienced CDMO investor, H.I.G. Capital

BioVectra Inc. excited for continued growth under experienced CDMO investor, H.I.G. Capital

CHARLOTTETOWN – November 04, 2019 – Today, H.I.G. Capital, a leading global private equity investment firm with over $34 billion of equity capital under management, announced that one of its affiliates has completed the acquisition of BioVectra Inc., a leading contract development and manufacturing organization (CDMO) of active pharmaceutical ingredients and intermediates, from Mallinckrodt Pharmaceuticals.

“We are excited to enter into this new chapter with H.I.G. Capital.” said Oliver Technow, Chief Executive Officer of BioVectra. “We have been fortunate over the last few years with the support of Mallinckrodt Pharmaceuticals to execute on our strategic growth plan.  We look ahead to continuing on this path with H.I.G. Capital, an experienced investor in the CDMO space.  H.I.G. is committed to our strategy and management team, and we look forward to continuing to pursue the company’s various growth initiatives.”

“We are very pleased to partner with Oliver Technow as well as his exceptional leadership team and dedicated employees,” said Mike Gallagher, Managing Director at H.I.G. Capital. “Oliver and his team have expanded BioVectra’s presence by pursuing strategic capital expenditure programs to significantly expand capacity.  We believe the company is well positioned to capitalize on the growing demand for its broad set of technical capabilities and exceptional quality track record.”

Entering their 50th year, BioVectra’s highly-skilled employees and recent expansions to support active pharmaceutical ingredient production capacity in Charlottetown, Prince Edward Island and biologics capabilities in Windsor, Nova Scotia, will be major drivers of the company’s growth plans. “Make no mistake,” said Technow. “This fantastic opportunity with H.I.G. Capital is a direct reflection of the dedicated team we have and the incredibly supportive environment we operate in. Everyone at BioVectra looks forward to continued growth and success right here in Atlantic Canada!”

About BioVectra

BioVectra is a CDMO that serves global pharmaceutical and biotech companies with full-service cGMP outsourcing solutions for intermediates and active pharmaceutical ingredients (APIs). An innovative and reliable service partner with a strong regulatory history, BioVectra specializing in:

  • cGMP microbial fermentation
  • Complex chemistry – high potency APIs
  • Biologics
  • Formulation development

For more information about BioVectra, please visit www.biovectra.com.

About H.I.G. Capital

H.I.G. is a leading global private equity and alternative assets investment firm with over $34 billion of equity capital under management.* Based in Miami, and with offices in New York, Boston, Chicago, Dallas, Los Angeles, San Francisco, and Atlanta in the U.S., as well as international affiliate offices in London, Hamburg, Madrid, Milan, Paris, Bogotá, Rio de Janeiro and São Paulo, H.I.G. specializes in providing both debt and equity capital to small and mid-sized companies, utilizing a flexible and operationally focused/ value-added approach:

  1. H.I.G.’s equity funds invest in management buyouts, recapitalizations and corporate carve-outs of both profitable as well as underperforming manufacturing and service businesses.
  2. H.I.G.’s debt funds invest in senior, unitranche and junior debt financing to companies across the size spectrum, both on a primary (direct origination) basis, as well as in the secondary markets. H.I.G. is also a leading CLO manager, through its WhiteHorse family of vehicles, and manages a publicly traded BDC, WhiteHorse Finance.
  3. H.I.G.’s real estate funds invest in value-added properties, which can benefit from improved asset management practices.

Since its founding in 1993, H.I.G. has invested in and managed more than 300 companies worldwide. The firm’s current portfolio includes more than 100 companies with combined sales in excess of $30 billion. For more information, please refer to the H.I.G. website at www.higcapital.com.

Media Contact

Jordan MacGregor
Communications and Marketing Manager
BioVectra Inc.
jmacgregor@biovectra.com
902-566-9116 ext. 6376

November 4th, 2019|Articles, News|

Mallinckrodt Agrees to Sell BioVectra Inc. to H.I.G. Capital for $250 Million

Statement from BioVectra President, Oliver Technow, on BioVectra’s sale to H.I.G. Capital:

“We are very excited to enter into this new chapter with H.I.G. Capital! Under their stewardship we have a fantastic opportunity to continue building and growing our business right here in Atlantic Canada.”

Official press release:

Mallinckrodt Agrees to Sell BioVectra Inc. to H.I.G. Capital for $250 Million

— Transaction continues to advance Mallinckrodt’s strategic focus on branded biopharmaceuticals by monetizing a non-core business —

— H.I.G. Capital to support BioVectra leadership and its attractive growth plan —

STAINES-UPON-THAMES, United Kingdom and MIAMI – Sept. 10, 2019 – Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced it has entered into a definitive agreement to sell its wholly owned subsidiary BioVectra Inc. to an affiliate of H.I.G. Capital, a leading global private equity investment firm, for approximately $250 million, including fixed consideration of $175 million, comprised of an upfront payment of $135 million and a long-term note for $40 million, and contingent payments of up to $75 million, enabling Mallinckrodt to capture future BioVectra growth potential.

BioVectra is a contract development and manufacturing organization (CDMO) whose global client base includes many of the top biopharmaceutical companies in the world. The company has a unique mix of capabilities, with core growth engines in complex chemistry, biologics and drug development. BioVectra will continue to supply an active pharmaceutical ingredient supporting Mallinckrodt’s specialty brands business under a long-term arrangement. The transaction is anticipated to include all of BioVectra’s sites in Prince Edward Island and Nova Scotia, Canada, as well as its employee base.

“This transaction continues to advance Mallinckrodt’s strategic focus on branded, high-growth biopharmaceuticals by monetizing a non-core business,” said Mark Trudeau, President and Chief Executive Officer of Mallinckrodt. “While we recognize the longer-term growth potential for BioVectra, we believe that the structure of this deal enables us to participate in the future success of the business, and therefore we see this sale as the best option for both Mallinckrodt and BioVectra moving forward.”

“We are excited to support BioVectra’s exceptional leadership and highly dedicated employees,” said Mike Gallagher, Managing Director at H.I.G. Capital. “BioVectra demonstrates a tremendous ability to generate robust organic growth and utilizes a broad set of technical capabilities to deliver outstanding service and quality. They are completing major capital expenditure programs to significantly expand capacity and the company is well positioned to capitalize on growing demand for their services.”

The transaction is expected to close in the fourth quarter of 2019, subject to customary closing conditions. It is not anticipated that the sale will have any material tax impact to Mallinckrodt. The company intends to use the proceeds from this divestiture consistent with its previously disclosed capital allocation priorities.

Goldman Sachs & Co. LLC served as financial advisor and Latham & Watkins LLP served as legal advisor to Mallinckrodt in connection with the transaction.

Wells Fargo Securities LLC served as financial advisor and McDermott Will & Emery LLP served as legal advisor to H.I.G. Capital.

 

About BioVectra

BioVectra is a CDMO that serves global pharmaceutical and biotech companies with full-service cGMP outsourcing solutions for intermediates and active pharmaceutical ingredients (APIs). An innovative and reliable service partner with a strong regulatory history, BioVectra has over 45 years of experience specializing in:

  • cGMP microbial fermentation
  • Complex chemistry – high potency APIs
  • Biologics
  • Formulation development

For more information about BioVectra, please visit www.biovectra.com.

 

About Mallinckrodt

Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The company’s Specialty Brands reportable segment’s areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic drugs and active pharmaceutical ingredients. To learn more about Mallinckrodt, visit www.mallinckrodt.com.

Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission (SEC) disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.

 

About H.I.G. Capital

H.I.G. is a leading global private equity and alternative assets investment firm with more than $34 billion of equity capital under management.* Based in Miami, and with offices in New York, Boston, Chicago, Dallas, Los Angeles, San Francisco, and Atlanta in the U.S., as well as international affiliate offices in London, Hamburg, Madrid, Milan, Paris, Bogotá, Rio de Janeiro and São Paulo, H.I.G. specializes in providing both debt and equity capital to small and mid-sized companies, utilizing a flexible and operationally focused/value-added approach:

  1. I.G.’s equity funds invest in management buyouts, recapitalizations and corporate carve-outs of both profitable as well as underperforming manufacturing and service businesses.
  2. I.G.’s debt funds invest in senior, unitranche and junior debt financing to companies across the size spectrum, both on a primary (direct origination) basis, as well as in the secondary markets. H.I.G. is also a leading CLO manager, through its WhiteHorse family of vehicles, and manages a publicly traded BDC, WhiteHorse Finance.
  3. I.G.’s real estate funds invest in value-added properties, which can benefit from improved asset management practices.

Since its founding in 1993, H.I.G. has invested in and managed more than 300 companies worldwide. The firm’s current portfolio includes more than 100 companies with combined sales in excess of $30 billion. For more information, please refer to the H.I.G. website at www.higcapital.com.

*Based on total capital commitments managed by H.I.G. Capital and affiliates.

CAUTIONARY STATEMENTS RELATED TO FORWARD-LOOKING STATEMENTS

Statements in this document about Mallinckrodt that are not strictly historical, including statements regarding the proposed divestiture; the expected timetable for completion of the divestiture; the potential use of proceeds from the divestiture; payment on the long-term note and future contingent payments; future financial condition and operating results; economic, business, competitive and/or regulatory factors affecting Mallinckrodt’s businesses; and any other statements regarding events or developments that the company believes or anticipates will or may occur in the future, may be “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, and involve a number of risks and uncertainties.

There are a number of important factors that could cause actual events to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include risks and uncertainties related to, among other things: the parties’ ability to satisfy the conditions to the divestiture, and complete the divestiture on the anticipated timeline or at all; the buyer’s ability to make payments on the long-term note or future contingent payments; general economic conditions and conditions affecting the industries in which Mallinckrodt operates; the commercial success of Mallinckrodt’s products; Mallinckrodt’s ability to realize anticipated growth, synergies and cost savings from acquisitions; conditions that could necessitate an evaluation of Mallinckrodt’s goodwill and/or intangible assets for possible impairment; changes in laws and regulations; Mallinckrodt’s ability to successfully integrate acquisitions of operations, technology, products and businesses generally and to realize anticipated growth, synergies and cost savings; Mallinckrodt’s and Mallinckrodt’s licensers’ ability to successfully develop or commercialize new products; Mallinckrodt’s and Mallinckrodt’s licensers’ ability to protect intellectual property rights; Mallinckrodt’s ability to receive procurement and production quotas granted by the U.S. Drug Enforcement Administration; customer concentration; Mallinckrodt’s reliance on certain individual products that are material to its financial performance; cost containment efforts of customers, purchasing groups, third-party payers and governmental organizations; the reimbursement practices of a small number of public or private insurers; pricing pressure on certain of Mallinckrodt’s products due to legal changes or changes in insurers’ reimbursement practices resulting from recent increased public scrutiny of healthcare and pharmaceutical costs; limited clinical trial data for Acthar Gel; complex reporting and payment obligations under healthcare rebate programs; Mallinckrodt’s ability to navigate price fluctuations; future changes to U.S. and foreign tax laws; Mallinckrodt’s ability to achieve expected benefits from restructuring activities; complex manufacturing processes; competition; product liability losses and other litigation liability; ongoing governmental investigations; material health, safety and environmental liabilities; retention of key personnel; conducting business internationally; the effectiveness of information technology infrastructure; and cybersecurity and data leakage risks; Mallinckrodt’s substantial indebtedness and its ability to generate sufficient cash to reduce its indebtedness; and any future actions taken with respect to the Specialty Generics business.

These and other factors are identified and described in more detail in the “Risk Factors” section of Mallinckrodt’s Annual Report on Form 10-K for the fiscal year ended December 28, 2018. The forward-looking statements made herein speak only as of the date hereof and Mallinckrodt does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise, except as required by law.

CONTACTS

Investor Relations
Mallinckrodt:

Daniel J. Speciale, CPA
Vice President, Investor Relations and IRO
314-654-3638
daniel.speciale@mnk.com

Media
Mallinckrodt:

Daniel Yunger
Kekst CNC
212-521-4879
mallinckrodt@kekstcnc.com

BioVectra:

Jordan MacGregor
Communications and Marketing Manager
BioVectra Inc.
902-566-9116 ext. 6376
jmacgregor@biovectra.com

H.I.G. Capital:

Mike Gallagher
Managing Director
305-379-2322
mgallagher@higcapital.com

September 10th, 2019|News|

BioVectra Inc. Announces the Offer of High Quality, Fully Synthetic cGMP Cannabidiol (CBD) Active Pharmaceutical Ingredient (API)

BioVectra Inc. Announces the Offer of High Quality, Fully Synthetic cGMP Cannabidiol (CBD) Active Pharmaceutical Ingredient (API)

Charlottetown, Prince Edward Island, Canada (March 17, 2019) – BioVectra Inc., a U.S. Food and Drug Administration- and Health Canada-inspected and approved Contract Development and Manufacturing Organization (CDMO), announces the offer of high quality, fully synthetic cGMP CBD API for clinical and commercial applications. BioVectra’s efficient cGMP CBD manufacturing process allows for the production of hundreds of kilograms, with the ability to scale-up to multi-metric ton quantities. This scale-up and supporting regulatory experience is a key competency for BioVectra, which can be applied to additional cannabinoid derivatives. Production is on-going for intermediate-scale batches, with process validation and submission of a Drug Master File to follow.

Located in Canada, BioVectra is uniquely positioned as a global supplier of synthetic cGMP CBD. The company can offer material supply, as well as product storage services as required.

BioVectra has a history of working in cannabinoids, dating back to the early 2000s, when it developed a supply of dronabinol. Building off its existing strengths in complex synthetic chemistry and natural product purifications, the company’s ability to manufacture synthetic cGMP CBD complements increased market demand. BioVectra looks forward to continuing to supply its current and new customers with this pharmaceutically important compound.

For more information, please contact BioVectra at cbd@biovectra.com or 866-883-2872 to discuss your CBD requirements.

About BioVectra

BioVectra is a CDMO that serves global pharmaceutical and biotech companies with full-service cGMP outsourcing solutions for intermediates and active pharmaceutical ingredients. An innovative and reliable service partner with a strong regulatory history, BioVectra has over 45 years of experience specializing in:

  • cGMP Microbial Fermentation
  • Complex Chemistry – High Potency APIs
  • Biologics
  • Formulation Development

For more information about BioVectra, please visit www.biovectra.com.

Contact

Fahim Naeem, Business Development Manager
BioVectra Inc.
Phone: 866-883-2872
E-Mail: cbd@biovectra.com

March 17th, 2019|News|

BioVectra Inc. Invests $1.5M in Large-Scale Synthetic Reactor Replacements and Analytical Development Capabilities

BioVectra Inc. Invests $1.5M in Large-Scale Synthetic Reactor Replacements and Analytical Development Capabilities

BioVectra Inc., a global Contract Development and Manufacturing Organization (CDMO), today announced new investments in its large-scale synthetic chemistry and analytical development capabilities. To continue serving its client’s cGMP manufacturing needs, BioVectra completed the replacement of two 4,000L vessels used for small molecule synthesis.

“These vessels have been very important for advancing our clients’ programs into later-stage clinical trials,” said Matt Frizzle, BioVectra’s Director of Business Development, CMO Services. “They are highly critical when larger quantities of Active Pharmaceutical Ingredients (APIs) are needed and, in particular, through commercial supply.” For earlier stages of research, BioVectra operates several cGMP kilo labs, with access to reactors in the range of 30-800L.

Additionally, BioVectra announced an enhancement of its analytical capabilities through the purchase of new equipment. “These investments help ensure our process development team has adequate control and specifications to meet regulatory requirements,” said Dr. Marc Sauer, BioVectra’s Vice President of Research and Development.  BioVectra’s suite of analytical equipment will be bolstered with the addition of two UPLCs and five HPLCs, two Charged Aerosol Detectors (CAD), two single quad mass detectors, a XRPD unit, an ICP-MS, a particle surface area and a DSC/TGA instrument.

Combined these investments were in the order of $1.5M, and were made to enhance BioVectra’s overall API service offering to our global biotechnology and pharmaceutical partners.

About BioVectra

BioVectra is a CDMO that serves global pharmaceutical and biotech companies with full-service cGMP outsourcing solutions for intermediates and active pharmaceutical ingredients. An innovative and reliable service partner with a strong regulatory history, BioVectra has over 45 years of experience specializing in:

  • cGMP Microbial Fermentation
  • Complex Chemistry – High Potency APIs
  • Biologics
  • Formulation Development

For more information about BioVectra, please visit www.biovectra.com.

Media Contact

Jordan MacGregor

Marketing and Communications Manager

jmacgregor@biovectra.com

902-566-9116 ext. 6376

March 15th, 2019|News|

Enhancing capabilities, hiring top-talent and growing our operations!

BioVectra announces five-year, $144.6m expansion project intended to support on-going API production capacity and enhancement of Biologics capabilities, including a mammalian cell culture facility. Over the lifespan of the project, 150 high-skilled, full-time jobs are expected to be created on Prince Edward Island and in Nova Scotia.

Additionally, BioVectra invests $1.5m in large-scale synthetic reactor replacements and analytical development capabilities.

Connect with us at DCAT Week (info@biovectra.com) to learn more about our exciting investments and growth!

March 7th, 2019|Uncategorised|

BioVectra wins BIOTECanada’s Gold Leaf Award for Company of the Year!

CANADIAN BIOTECH INDUSTRY RECOGNIZES TOP PERFORMERS DURING GLOBAL BIOTECH WEEK

September 26, 2018 [OTTAWA] – BIOTECanada is pleased to announce the 2018 winners of the Gold Leaf Awards which annually highlight innovation and entrepreneurship within the Canadian biotechnology industry. This national celebration of the Canadian industry represents an outstanding collection of companies and individuals who have helped lead the industry throughout 2018.

“The remarkable individuals and companies we recognize through the Gold Leaf Awards are great examples of the core strengths of Canada’s biotech ecosystem including scientific excellence and passion,” commented Andrew Casey, President and CEO of BIOTECanada. “Importantly, Canada’s global biotech success is founded in its ability to advance scientific innovation by leveraging a diverse and vibrant ecosystem comprised of individuals, companies and institutions located in every province across the country. It is this strength that establishes Canada’s biotech industry as a leader in developing the solutions that will help address the global social and economic opportunities emerging from population growth and a changing climate.”

2018 BIOTECanada Gold Leaf Winners:

  • Aspect Biosystems Ltd. (Emerging Company of the Year)
  • BioVectra Inc. (Company of the Year)
  • CDRD – The Centre for Drug Research and Development (Ecosystem Builder)
  • Wilf Keller, CEO Ag-West Bio (Industry Leadership)

“To be selected as BIOTECanada’s Emerging Company of the Year, among so many notable biotech companies across the country, is a true honour,” said Tamer Mohamed, Aspect’s President and CEO. “We are inspired by the profound impact regenerative medicine therapies can have on patients around the globe and our team is committed to realizing this impact from right here in Canada.”

“On behalf of BioVectra, it is an honour to win BIOTECanada’s 2018 Gold Leaf Award for Biotech Company of the Year,” said Oliver Technow, President of BioVectra. “Our team has accomplished a lot over the past year. Our new biologics facility is now online in Windsor, Nova Scotia, we are making tremendous progress on an expansion at our headquarters in Charlottetown, Prince Edward Island, and we continue to build upon our capabilities, our development experience, and our technologies so that we can grow alongside our partners and help them advance their clinical programs efficiently. None of this would be possible without our highly dedicated and specialized employees. This award is truly a testament to their hard work and tenacity!”

“We are honoured that CDRD has been chosen to receive the BIOTECanada Gold Leaf Ecosystem Builder Award. This award is a testament to the tremendous dedication and hard work of each and every one of our team of 100+ scientists and business people; and the success they have achieved in commercializing innovation, attracting investment, supporting globally competitive Canadian companies; and helping generate long term, highly-skilled employment opportunities for Canadians – for moving us towards our Vision of being catalyst for Canada life sciences leading the world,” said Gordon C. McCauley, President and CEO of CDRD.

“It’s a great surprise and honour to receive the Gold Leaf Award from BioteCanada, an national entity that does the very important job coordinating and supporting biotech research. I’ve had the privilege of working with so many great people. It’s all about teamwork; I’ve been able to work with many excellent teams over the years. I look forward to continuing to contribute in any way I can.”

Global Biotech Week running September 24 – 30, 2018 brings together domestic and international biotechnology associations will experience hundreds of events across 20 countries. With thousands of participants each year, Global Biotech Week provides an opportunity to collaborate and showcase the impact biotechnology is having on economies celebrating science, innovation, and solutions.

September 26th, 2018|News|

Whitepaper: An Innovative Approach to Manufacturing Biologics Using Microbial Fermentation

Whitepaper: An Innovative Approach to Manufacturing Biologics Using Microbial Fermentation

Overview


The use of microbial fermentation to make biologics is growing rapidly. A manufacturing platform is an increasingly popular way to speed up process development stages and get a biologic to market faster. High-throughput systems can speed up optimization of each of these platform steps. Single-use, disposable technologies are starting to replace stainless steel to streamline biologic manufacturing, reduce costs, minimize contamination risks and allow rapid expansion of capacity.

Key Learning Objectives

  • What a platform technology is and how it can speed up process development.
  • How high-throughput technologies can be used in biologic process development.
  • What single-use, disposable technologies are currently on the market for biologics manufacturing and the advantages of using them.

Brought to you by

BioVectra logo

Please complete the form to download the whitepaper.
Please select all that apply.
Please select all that apply.
August 1st, 2018|Articles|

BioVectra and TUBE Biopharmaceuticals Sign Exclusive License for Microbial Fermentation Technology to Manufacture Tubulysins

BioVectra and TUBE Biopharmaceuticals Sign Exclusive License for Microbial Fermentation Technology to Manufacture Tubulysins

16/07/18 – CHARLOTTETOWN, Prince Edward Island, Canada – Today, BioVectra Inc., a global Contract Development and Manufacturing Organization (CDMO) with microbial fermentation and synthesis capabilities with high containment, and TUBE Biopharmaceuticals GmbH, an Austrian biotech company active in the research field of cytotoxic payloads, announced that they have signed an exclusive license agreement for microbial fermentation technology to manufacture tubulysins.

After conducting further development, optimization and upscaling of the strain initially developed by TUBE Biopharmaceuticals, BioVectra intends to provide the marketplace with research- and cGMP-grade tubulysins and downstream derivatives.

Tubulysins belong to a cytotoxic tetrapeptidic natural product class that result in disruption of microtubule networks and inhibition of tubulin polymerization of cancer cells, and are suitable for use in conjugation approaches such as Antibody Drug Conjugates (ADCs), specifically targeting drug-resistant cancers.

Financial details of this unlimited agreement were not disclosed.

For more information, please contact Jordan MacGregor, at jmacgregor@biovectra.com.

About BioVectra

BioVectra is a CDMO that serves global pharmaceutical and biotech companies with full-service cGMP outsourcing solutions for intermediates and active pharmaceutical ingredients. An innovative and reliable service partner with a strong regulatory history, BioVectra has over 45 years of experience specializing in:

  • cGMP Microbial Fermentation
  • Complex Chemistry – High Potency APIs
  • Biologics
  • Formulation Development

For more information about BioVectra, please visit www.biovectra.com.

About TUBE Biopharmaceuticals

TUBE Pharmaceuticals GmbH (www.tubepharma.